This study seeks to determine whether daily administration of oral insulin, from the age of 4–7 months until the age of 36 months to children with elevated genetic risk for T1D, reduces the incidence of beta cell autoantibodies and diabetes (51). The gene discussed is INS; the disease is type 1 diabetes mellitus.